TBPH · Theravance Biopharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $107.46M | $64.38M | $57.42M | $51.35M | $55.31M | $71.86M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $37.41M | $37.64M | $40.62M | $63.39M | $193.66M | $260.95M |
| SG&A | $73.65M | $69.17M | $70.09M | $67.07M | $99.30M | $108.66M |
| Total Operating Expenses | $111.07M | $111.33M | $113.46M | $143.30M | $313.10M | $369.61M |
| D&A | $1.50M | $1.60M | $1.90M | $2.60M | $3.50M | $3.30M |
| Operating Income | ($3.60M) | ($46.95M) | ($56.03M) | ($91.96M) | ($257.78M) | ($297.76M) |
| Interest Expense | $2.46M | $2.55M | $2.35M | $6.37M | $46.89M | $44.59M |
| Income Tax | $23.35M | $11.80M | $5.92M | $9.0K | ($151.0K) | ($8.52M) |
| Net Income | $105.89M | ($56.42M) | ($55.19M) | $872.13M | ($199.43M) | ($278.02M) |
| EPS - Basic | $2.10 | ($1.15) | ($1.00) | $11.85 | ($4.46) | - |
| EPS - Diluted | $2.06 | ($1.15) | ($1.00) | $11.85 | ($4.46) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $167.81M | $37.80M | $39.55M | $298.17M | $89.96M | $81.47M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.57M | $2.24M | $1.52M | $1.55M | $3.10M | $6.78M |
| Current Assets | $418.46M | $161.07M | $133.54M | $353.46M | $249.87M | $393.34M |
| Total Assets | $485.57M | $354.16M | $382.00M | $607.40M | $374.82M | $469.06M |
| Current Liabilities | $38.30M | $32.09M | $24.77M | $28.71M | $58.59M | $123.57M |
| Long-term Debt | - | - | $0 | - | $616.33M | $619.17M |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $296.72M | $175.54M | $213.00M | $441.80M | ($338.57M) | ($303.75M) |
| Retained Earnings | ($859.63M) | ($965.52M) | ($909.10M) | ($853.91M) | ($1.73B) | ($1.53B) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $238.54M | ($11.54M) | ($27.00M) | ($186.99M) | ($207.86M) | ($250.40M) |
| Investing Cash Flow | ($105.28M) | $12.28M | ($32.70M) | $1.15B | $124.49M | $10.72M |
| Financing Cash Flow | ($3.25M) | ($2.50M) | ($198.93M) | ($758.81M) | $91.86M | $263.08M |
| CapEx | $42.0K | $332.0K | $2.49M | $572.0K | $3.41M | $6.62M |
| Free Cash Flow | $238.50M | ($11.87M) | ($29.48M) | ($187.56M) | ($211.26M) | ($257.02M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -3.4% | -72.9% | -97.6% | -179.1% | -466.1% | -414.4% |
| EBITDA margin | -2.0% | -70.4% | -94.3% | -174.0% | -459.7% | -409.8% |
| Net margin | 98.5% | -87.6% | -96.1% | 1698.5% | -360.6% | -386.9% |
| Free cash flow margin | 221.9% | -18.4% | -51.3% | -365.3% | -382.0% | -357.7% |
| FCF / Net income | 2.25 | 0.21 | 0.53 | -0.22 | 1.06 | 0.92 |
| R&D / Revenue | 34.8% | 58.5% | 70.7% | 123.5% | 350.1% | 363.2% |
| SG&A / Revenue | 68.5% | 107.4% | 122.1% | 130.6% | 179.5% | 151.2% |
| Effective tax rate | 18.1% | - | - | 0.0% | - | - |
| Return on assets | 21.8% | -15.9% | -14.4% | 143.6% | -53.2% | -59.3% |
| Return on equity | 35.7% | -32.1% | -25.9% | 197.4% | 58.9% | 91.5% |
| Return on invested capital | - | - | -20.8% | - | -73.3% | -74.6% |
| Liquidity | ||||||
| Current ratio | 10.93 | 5.02 | 5.39 | 12.31 | 4.26 | 3.18 |
| Quick ratio | 10.93 | 5.02 | 5.39 | 12.31 | 4.26 | 3.18 |
| Cash ratio | 4.38 | 1.18 | 1.60 | 10.38 | 1.54 | 0.66 |
| Leverage | ||||||
| Debt / Equity | - | - | 0.00 | - | -1.82 | -2.04 |
| Debt / Assets | - | - | 0.00 | - | 1.64 | 1.32 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -1.5x | -18.4x | -23.8x | -14.4x | -5.5x | -6.7x |
| Equity multiplier | 1.64 | 2.02 | 1.79 | 1.37 | -1.11 | -1.54 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.22 | 0.18 | 0.15 | 0.08 | 0.15 | 0.15 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 9.1x | - | - | 0.9x | - | - |
| P / B | 3.2x | 2.6x | 2.9x | 1.9x | - | - |
| P / S | 9.0x | 7.1x | 10.8x | 16.1x | 13.9x | 15.4x |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 66.9% | 12.1% | 11.8% | -7.2% | -23.0% | -2.1% |
| Revenue CAGR (3y) | 27.9% | 5.2% | -7.2% | -11.2% | 4.4% | 67.2% |
| Revenue CAGR (5y) | 8.4% | -2.6% | 3.4% | 27.3% | 2.6% | 11.3% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 92.3% | 16.2% | 39.1% | 64.3% | 13.4% | -18.2% |
| Net income growth (YoY) | - | -2.2% | - | - | 28.3% | -17.6% |
| EPS growth (YoY) | - | -15.0% | - | - | - | - |
| EPS CAGR (3y) | -44.2% | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | 59.8% | 84.3% | 11.2% | 17.8% | -6.5% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 69.0% | -17.6% | -51.8% | - | -11.5% | -35.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$107.46M totalSingle Reportable Segment$107.46M · 100.0%
Product / service
$233.27M totalYupelri Monotherapy$93.31M · 40.0%
Collaborative Arrangement Revenue$74.96M · 32.1%
Licensing And Milestone$32.50M · 13.9%
Milestone$25.00M · 10.7%
License$7.50M · 3.2%
Geographic
$107.46M totalUS$74.96M · 69.8%
Europe$32.50M · 30.2%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Theravance Biopharma against the 5 most active filers in the same SIC group.